Central nervous system involvement in cardiac amyloidosis: Redefining the heart-brain axis.
| Title: | Central nervous system involvement in cardiac amyloidosis: Redefining the heart-brain axis. |
|---|---|
| Authors: | Giamundo DM; Department of Systems Medicine, 'Tor Vergata' University, Rome, Italy.; Cassataro G; Department of Medicine and Pulmonology, Fondazione Istituto 'G. Giglio', Cefalù, Italy.; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Palermo, Italy.; Ministrini S; Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.; Department of Cardiology, Luzerner Kantonsspital, Lucerne, Switzerland.; Stämpfli SF; Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.; Department of Cardiology, Luzerner Kantonsspital, Lucerne, Switzerland. |
| Source: | European journal of clinical investigation [Eur J Clin Invest] 2026 Jan; Vol. 56 (1), pp. e70122. Date of Electronic Publication: 2025 Sep 23. |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: Wiley Country of Publication: England NLM ID: 0245331 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2362 (Electronic) Linking ISSN: 00142972 NLM ISO Abbreviation: Eur J Clin Invest Subsets: MEDLINE |
| Imprint Name(s): | Publication: Oxford : Wiley; Original Publication: Berlin, New York, Springer-Verlag, on behalf of the European Society for Clinical Investigation. |
| MeSH Terms: | Amyloidosis*/physiopathology ; Amyloidosis*/complications ; Cardiomyopathies*/physiopathology ; Cardiomyopathies*/complications ; Cognitive Dysfunction*/physiopathology ; Cognitive Dysfunction*/etiology; Brain/physiopathology ; Humans |
| Abstract: | Background: Amyloidosis is characterised by the extracellular accumulation of misfolded proteins forming amorphous aggregates called amyloid. Cardiac amyloidosis results from myocardial involvement in systemic amyloidosis, leading to impaired heart function. Besides myocardial involvement, cardiac amyloidosis may also directly and indirectly affect the central nervous system.; Methods: This narrative review summarises current evidence about on central nervous system involvement in cardiac amyloidosis and the pathophysiological mechanisms linking heart and brain in the context of this systemic disease.; Results: Although the pathophysiological relationship between cardiac amyloidosis and cognitive decline remains poorly understood, central nervous system involvement likely results from the complex interplay of direct amyloid deposition, cerebrovascular changes, and cardiac dysfunction.; Conclusion: The growing awareness of cognitive impairment in patients with cardiac amyloidosis highlights the need for further research and supports a multidisciplinary approach in the assessment and management of affected individuals.; (© 2025 The Author(s). European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.) |
| References: | Circ Cardiovasc Imaging. 2023 Jul;16(7):523-535. (PMID: 37431665); Circ Res. 2004 Apr 30;94(8):1008-10. (PMID: 15044325); Cardiovasc Pathol. 2006 Sep-Oct;15(5):287-290. (PMID: 16979036); J Am Heart Assoc. 2013 Apr 22;2(2):e000098. (PMID: 23608605); Int J Mol Sci. 2021 Jan 22;22(3):. (PMID: 33499149); Vascul Pharmacol. 2024 Sep;156:107411. (PMID: 39029855); Intern Med. 2018 Dec 1;57(23):3351-3355. (PMID: 30101921); Eur J Clin Invest. 2025 Jul;55(7):e70049. (PMID: 40247650); Ann Neurol. 1997 Mar;41(3):307-13. (PMID: 9066351); Acta Neuropathol. 2004 Apr;107(4):283-91. (PMID: 14986026); Bull Exp Biol Med. 2016 Apr;160(6):844-9. (PMID: 27160887); J Intern Med. 2004 Feb;255(2):159-78. (PMID: 14746554); Cells. 2021 Jul 13;10(7):. (PMID: 34359938); Amyloid. 2021 Mar;28(1):12-18. (PMID: 32981389); Front Cardiovasc Med. 2024 May 13;11:1386733. (PMID: 38803660); Nitric Oxide. 2022 May 1;122-123:6-18. (PMID: 35202833); Mol Neurobiol. 2025 Mar;62(3):2945-2954. (PMID: 39192044); J Intern Med. 2021 Jun;289(6):895-905. (PMID: 33274477); J Am Coll Cardiol. 2016 Sep 20;68(12):1323-41. (PMID: 27634125); Amyloid. 2024 Dec;31(4):285-290. (PMID: 39153196); ESC Heart Fail. 2022 Feb;9(1):11-20. (PMID: 34784656); Biochim Biophys Acta. 2014 Sep;1842(9):1340-9. (PMID: 24747741); Amyloid. 2003 Sep;10(3):160-84. (PMID: 14640030); Amyloid. 2022 Mar;29(1):1-7. (PMID: 34783272); Eur J Heart Fail. 2020 Oct;22(10):1852-1862. (PMID: 32078212); Am J Physiol Heart Circ Physiol. 2019 May 1;316(5):H1158-H1166. (PMID: 30875258); Neurology. 2021 Dec 14;97(24):1111-1119. (PMID: 34663645); Radiol Clin North Am. 2023 May;61(3):551-562. (PMID: 36931769); FEBS Lett. 2009 Aug 20;583(16):2691-9. (PMID: 19527723); Amyloid. 2019 Sep;26(3):128-138. (PMID: 31172799); Biomark Med. 2016 Jul;10(7):743-55. (PMID: 27338783); Heart Vessels. 2025 Feb;40(2):131-139. (PMID: 39073423); Alzheimers Dement. 2024 Nov;20(11):7518-7528. (PMID: 39387105); Circulation. 2012 Sep 4;126(10):1286-300. (PMID: 22949539); J Neurol. 2018 Feb;265(2):299-307. (PMID: 29209781); JACC Case Rep. 2021 Mar 17;3(3):450-454. (PMID: 34317556); Amyloid. 2012 Dec;19(4):191-6. (PMID: 23126591); Am J Cardiol. 1983 Jul;52(1):137-46. (PMID: 6858901); Am J Pathol. 1989 Feb;134(2):243-51. (PMID: 2464938); Neuropathology. 2018 Feb;38(1):11-21. (PMID: 28960480); J Am Coll Cardiol. 2020 Mar 3;75(8):942-951. (PMID: 32130930); Neurology. 2016 Aug 23;87(8):773-81. (PMID: 27466465); N Engl J Med. 1992 Nov 26;327(22):1570-3. (PMID: 1435884); Neurol Sci. 2020 May;41(5):1163-1170. (PMID: 31897943); Eur Heart J Qual Care Clin Outcomes. 2025 Nov 4;11(7):1015-1022. (PMID: 40392964); Amyloid. 2018 Mar;25(1):46-53. (PMID: 29369708); J Am Coll Cardiol. 1984 Jan;3(1):107-13. (PMID: 6317729); Eur Heart J. 2020 Aug 1;41(29):2759-2767. (PMID: 32267922); Immunol Rev. 2022 Nov;312(1):61-75. (PMID: 35708588); N Engl J Med. 2023 Jul 20;389(3):239-250. (PMID: 37212440); J Stroke Cerebrovasc Dis. 2015 Jun;24(6):e149-51. (PMID: 25802113); J Thorac Cardiovasc Surg. 2015 Nov;150(5):1292-301.e2. (PMID: 26344687); JACC Clin Electrophysiol. 2020 Apr;6(4):351-361. (PMID: 32327068); Ann Neurol. 2024 Sep;96(3):423-440. (PMID: 38923548); Eur J Clin Invest. 2024 Jun;54(6):e14160. (PMID: 38217112); JACC Cardiovasc Imaging. 2014 May;7(5):511-4. (PMID: 24831211); Blood. 2016 Aug 25;128(8):1144-51. (PMID: 27389717); JACC Cardiovasc Imaging. 2025 Apr;18(4):478-499. (PMID: 39797879); Eur J Heart Fail. 2022 Nov;24(11):2019-2028. (PMID: 35920110); Circulation. 2007 Nov 20;116(21):2420-6. (PMID: 17984380); Eur Heart J. 2017 Oct 07;38(38):2879-2887. (PMID: 29019612); Eur J Clin Invest. 2026 Jan;56(1):e70122. (PMID: 40985278); Br Heart J. 1995 Nov;74(5):541-4. (PMID: 8562243); Circulation. 2019 Jan 22;139(4):431-443. (PMID: 30586695); JACC Adv. 2024 Jul 22;3(9):101123. (PMID: 39140080); J Neuropathol Exp Neurol. 2020 Oct 1;79(10):1134-1136. (PMID: 32856080); Handb Clin Neurol. 2013;115:659-81. (PMID: 23931809); JAMA. 2001 May 9;285(18):2370-5. (PMID: 11343485); Amyloid. 2005 Dec;12(4):216-25. (PMID: 16399646); Eur Heart J. 2024 Sep 29;45(36):3314-3414. (PMID: 39210723); Lancet. 2016 Jun 25;387(10038):2641-2654. (PMID: 26719234); Eur Heart J. 2004 Jul;25(14):1237-41. (PMID: 15246642); Amyloid. 2015;22(3):147-55. (PMID: 25997105); Eur Heart J Case Rep. 2023 May 08;7(5):ytad239. (PMID: 37223323); Curr Opin Pharmacol. 2006 Apr;6(2):214-20. (PMID: 16483845); Heart Fail Clin. 2022 Jul;18(3):479-488. (PMID: 35718420); Heart. 1996 Apr;75(4):426. (PMID: 8705775); Stroke. 2018 Jan;49(1):40-45. (PMID: 29247143); Clin Med (Lond). 2018 Apr 1;18(Suppl 2):s30-s35. (PMID: 29700090); Heart Fail Rev. 2022 Sep;27(5):1471-1484. (PMID: 34694575); Neurol Res. 2023 Aug;45(8):773-778. (PMID: 37132627); Circulation. 2002 Oct 15;106(16):2091-7. (PMID: 12379579); Eur Heart J. 2021 Apr 21;42(16):1554-1568. (PMID: 33825853); PeerJ. 2014 Jul 22;2:e493. (PMID: 25097823); Int J Cardiol. 2022 Jul 1;358:65-71. (PMID: 35439584); Neurology. 2007 Aug 14;69(7):693-8. (PMID: 17698792); Int J Cardiol. 2021 Apr 15;329:144-147. (PMID: 33358831); N Engl J Med. 2021 Aug 05;385(6):493-502. (PMID: 34215024); J Pathol. 1987 Dec;153(4):395-8. (PMID: 3430237); Nat Rev Cardiol. 2015 Feb;12(2):91-102. (PMID: 25311231); Amyloid. 2021 Sep;28(3):168-172. (PMID: 33877023); Clin Auton Res. 2019 Apr;29(2):245-251. (PMID: 29511897); Molecules. 2021 Aug 22;26(16):. (PMID: 34443678); Circulation. 2009 Sep 29;120(13):1203-12. (PMID: 19752327); J Neurol Sci. 2023 Nov 15;454:120866. (PMID: 37931443); J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):159-67. (PMID: 25091367); Can J Cardiol. 2020 Mar;36(3):432-440. (PMID: 32145870); Heart Fail Clin. 2024 Jul;20(3):317-323. (PMID: 38844302); J Neurol. 2016 Nov;263(11):2336-2338. (PMID: 27730377); Eur J Heart Fail. 2022 Aug;24(8):1387-1396. (PMID: 35650018); N Engl J Med. 2018 Sep 13;379(11):1007-1016. (PMID: 30145929); Acta Neuropathol. 2023 Jan;145(1):113-126. (PMID: 36198883); Radiology. 2015 Nov;277(2):388-97. (PMID: 25997029) |
| Grant Information: | GAMBIT Gemeinnützige Stiftung; Pfizer Competitive Research |
| Contributed Indexing: | Keywords: amyloidosis; cardiac amyloidosis; cognitive decline; ischemic stroke; neurodegeneration; systemic amyloidosis |
| Entry Date(s): | Date Created: 20250923 Date Completed: 20260117 Latest Revision: 20260119 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC12811839 |
| DOI: | 10.1111/eci.70122 |
| PMID: | 40985278 |
| Database: | MEDLINE |
Journal Article; Review